T. Rowe Price Associates
TBPH icon

T. Rowe Price Associates’s Theravance Biopharma TBPH Stock Holding History

T. Rowe Price Associates’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
75,140
+9,031
+14% +$160K ﹤0.01% 2054
2025
Q4 		$1.24M Buy
66,109
+1,969
+3% +$32.7K ﹤0.01% 1987
2025
Q3 		$937K Buy
64,140
+1,708
+3% +$21.6K ﹤0.01% 2102
2025
Q2 		$689K Buy
62,432
+1,588
+3% +$15.4K ﹤0.01% 2150
2025
Q1 		$544K Sell
60,844
-3,951
-6% -$36.8K ﹤0.01% 2219
2024
Q4 		$610K Buy
64,795
+9,315
+17% +$84.8K ﹤0.01% 2200
2024
Q3 		$448K Buy
55,480
+7,700
+16% +$66.7K ﹤0.01% 2296
2024
Q2 		$406K Sell
47,780
-1,695
-3% -$15.3K ﹤0.01% 2277
2024
Q1 		$444K Buy
49,475
+3,532
+8% +$32.7K ﹤0.01% 2256
2023
Q4 		$517K Sell
45,943
-2,080
-4% -$20.9K ﹤0.01% 2152
2023
Q3 		$415K Buy
48,023
+5,043
+12% +$48.7K ﹤0.01% 2201
2023
Q2 		$445K Buy
42,980
+5,064
+13% +$55.9K ﹤0.01% 2193
2023
Q1 		$412K Buy
37,916
+948
+3% +$10K ﹤0.01% 2191
2022
Q4 		$415K Sell
36,968
-43,609
-54% -$458K ﹤0.01% 2219
2022
Q3 		$818K Buy
80,577
+9,264
+13% +$86.8K ﹤0.01% 1863
2022
Q2 		$646K Buy
71,313
+25,905
+57% +$239K ﹤0.01% 2107
2022
Q1 		$434K Buy
45,408
+4,347
+11% +$42.6K ﹤0.01% 2398
2021
Q4 		$454K Sell
41,061
-9,500
-19% -$82.8K ﹤0.01% 2429
2021
Q3 		$374K Buy
50,561
+14,724
+41% +$165K ﹤0.01% 2500
2021
Q2 		$520K Sell
35,837
-1,937
-5% -$36.4K ﹤0.01% 2378
2021
Q1 		$771K Sell
37,774
-408,677
-92% -$7.77M ﹤0.01% 2175
2020
Q4 		$7.93M Sell
446,451
-97,929
-18% -$1.76M ﹤0.01% 1385
2020
Q3 		$8.05M Buy
544,380
+19,919
+4% +$373K ﹤0.01% 1343
2020
Q2 		$11M Buy
524,461
+9,992
+2% +$257K ﹤0.01% 1276
2020
Q1 		$11.9M Sell
514,469
-11,969
-2% -$300K ﹤0.01% 1199
2019
Q4 		$13.6M Buy
526,438
+2,424
+0.5% +$47.1K ﹤0.01% 1261
2019
Q3 		$10.2M Sell
524,014
-615,356
-54% -$12.4M ﹤0.01% 1286
2019
Q2 		$18.6M Sell
1,139,370
-71,609
-6% -$1.45M ﹤0.01% 1196
2019
Q1 		$27.5M Sell
1,210,979
-22,083
-2% -$560K ﹤0.01% 1077
2018
Q4 		$31.6M Sell
1,233,062
-363,125
-23% -$9.8M 0.01% 985
2018
Q3 		$52.1M Sell
1,596,187
-144,593
-8% -$3.94M 0.01% 904
2018
Q2 		$39.5M Sell
1,740,780
-604,415
-26% -$14.4M 0.01% 976
2018
Q1 		$56.9M Buy
2,345,195
+29,655
+1% +$814K 0.01% 823
2017
Q4 		$64.6M Buy
2,315,540
+15,244
+0.7% +$451K 0.01% 771
2017
Q3 		$78.8M Buy
2,300,296
+980,855
+74% +$32.1M 0.01% 697
2017
Q2 		$52.6M Buy
1,319,441
+956,706
+264% +$36.8M 0.01% 800
2017
Q1 		$13.4M Buy
362,735
+74,370
+26% +$2.38M ﹤0.01% 1270
2016
Q4 		$9.19M Sell
288,365
-26,958
-9% -$836K ﹤0.01% 1333
2016
Q3 		$11.4M Buy
315,323
+104,560
+50% +$2.91M ﹤0.01% 1286
2016
Q2 		$4.78M Buy
210,763
+87,200
+71% +$1.88M ﹤0.01% 1406
2016
Q1 		$2.32M Sell
123,563
-12,790
-9% -$209K ﹤0.01% 1492
2015
Q4 		$2.23M Sell
136,353
-3,822
-3% -$60.7K ﹤0.01% 1515
2015
Q3 		$1.54M Buy
140,175
+15,490
+12% +$197K ﹤0.01% 1592
2015
Q2 		$1.62M Buy
124,685
+700
+0.6% +$10.9K ﹤0.01% 1631
2015
Q1 		$2.15M Sell
123,985
-218,963
-64% -$4.01M ﹤0.01% 1574
2014
Q4 		$5.12M Sell
342,948
-2,097
-0.6% -$36.5K ﹤0.01% 1457
2014
Q3 		$7.95M Buy
345,045
+241,149
+232% +$7M ﹤0.01% 1364
2014
Q2 		$3.31M Buy
+103,896
New +$3.13M ﹤0.01% 1505

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's TBPH Position: Q1 2026 in Review

T. Rowe Price Associates increased its Theravance Biopharma (TBPH) stake by 14% in Q1 2026, buying an estimated $160K and bringing the position to 75,140 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

T. Rowe Price Associates first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $78.8M in Q3 2017. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • T. Rowe Price Associates held 75,140 shares of Theravance Biopharma worth $1.22M as of Q1 2026.
  • T. Rowe Price Associates bought 9,031 Theravance Biopharma shares in Q1 2026, an estimated $160K.
  • Theravance Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2054 holding.
  • T. Rowe Price Associates first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
  • T. Rowe Price Associates's Theravance Biopharma position peaked at $78.8M in Q3 2017.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.